The importance of patient fitness in expert and multidisciplinary multiparametric management of HCC: a narrative review

Abstract

Hepatocellular carcinoma (HCC) management is a challenging task. Despite continuous efforts to develop more effective treatments, patient prognosis often remains poor. Recently, a new management concept - the “multiparametric therapeutic Hierarchy” - has been proposed, with the hypothetical advantage of avoiding the risk of undertreatment inherent in “classical” HCC management modalities while also minimizing the risk of overtreatment that may occur when inexperienced clinicians adopt overly aggressive treatment hierarchies. The “multiparametric” concept emphasizes a more comprehensive evaluation of each patient, focusing on their individual clinical presentation. Among the various factors considered, patient fitness plays a critical role. Here, fitness is understood as the set of patient-specific characteristics that can influence the outcomes of therapies within the hierarchical framework (or even preclude certain therapies altogether). This multifaceted concept extends beyond traditional “Performance Status” measurements, incorporating considerations of frailty and comorbidity. In this review, we explore the available evidence regarding the role of patient fitness within the multiparametric therapeutic hierarchy for HCC. Finally, we discuss fitness considerations across different levels of the therapeutic hierarchy, highlighting current evidence, existing challenges, and limitations, with the aim of providing new insights for physicians involved in HCC management.

Keywords

Hepatocellular carcinoma / therapeutic hierarchy / fitness / frailty

References

[1] Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[2] Cabibbo G, Aghemo A, Lai Q, Masarone M, Montagnese S, Ponziani FR; Italian Association for the Study of the Liver (AISF). Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Dig Liver Dis. 2022;54:452-60.

[3] Vitale A,Farinati F.Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy.Hepatology2020;72:2206-18

[4] Teufel A,Qian Y.Current trends and advancements in the management of hepatocellular carcinoma.Dig Dis2024;42:349-60

[5] Vitale A, Cabibbo G, Iavarone M, et al; HCC Special Interest Group of the Italian Association for the Study of the Liver. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023;24:e312-22.

[6] Kim KM,Jung SH.The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?.Liver Int2016;36:1490-7

[7] Roayaie S,Tabrizian P.The role of hepatic resection in the treatment of hepatocellular cancer.Hepatology2015;62:440-51

[8] Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma.J Hepatol2025;82:315-74

[9] Oken MM,Tormey DC et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol1982;5:649-55

[10] Karnofsky D A. The clinical evaluation of chemotherapeutic agents in cancer. Eval Chemother Agents 1949:191-205. Available from: https://scispace.com/papers/the-clinical-evaluation-of-chemotherapeutic-agents-in-cancer-12buycduj2. [Last accessed on 11 Jul 2025].

[11] Dolnikov S,Cherqui D.Liver transplantation in elderly patients: what do we know at the beginning of 2020?.Surg Today2020;50:533-9 PMCID:PMC7239827

[12] Cho E,Jun CH,Cho SB.A review of hepatocellular carcinoma in elderly patients focused on management and outcomes.In Vivo2019;33:1411-20 PMCID:PMC6755010

[13] Arora SP,Caird S.Hepatocellular carcinoma in older adults: a comprehensive review by Young International Society of Geriatric Oncology.J Geriatr Oncol2020;11:557-65 PMCID:PMC7188597

[14] Feinstein AR.The pre-therapeutic classification of co-morbidity in chronic disease.J Chronic Dis1970;23:455-68

[15] VanWagner LB,Whitsett M.A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR-OLT score.Hepatology2017;66:1968-79 PMCID:PMC5696007

[16] Dick AA,Seifert CF.Liver transplantation at the extremes of the body mass index.Liver Transpl2009;15:968-77

[17] Rimassa L,Czauderna C,Galle P.Systemic treatment of HCC in special populations.J Hepatol2021;74:931-43

[18] Lai Q,Gorgen A.Evaluation of the intention-to-treat benefit of living donation in patients with hepatocellular carcinoma awaiting a liver transplant.JAMA Surg2021;156:e213112 PMCID:PMC8281041

[19] Charlson ME,Ales KL.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.J Chronic Dis1987;40:373-83

[20] Volk ML,Lok AS.Modified Charlson comorbidity index for predicting survival after liver transplantation.Liver Transpl2007;13:1515-20

[21] Alaimo L,Lima HA.A comprehensive preoperative predictive score for post-hepatectomy liver failure after hepatocellular carcinoma resection based on patient comorbidities, tumor burden, and liver function: the CTF score.J Gastrointest Surg2022;26:2486-95

[22] Chang YS,Yen CL et al.The Charlson comorbidity index is an independent prognostic factor for treatment-naïve hepatocellular carcinoma patients with extrahepatic metastases.Hepatogastroenterology2015;62:1011-5

[23] Shinkawa H,Takemura S.Predictive value of the age-adjusted Charlson comorbidity index for outcomes after hepatic resection of hepatocellular carcinoma.World J Surg2020;44:3901-14

[24] Choi J,Choi Y.Modified Charlson comorbidity index as a survival prediction tool for older patients after liver transplantation.Ann Surg Treat Res2023;104:358-63 PMCID:PMC10277175

[25] Cabibbo G,Genco C,Cammà C.Causes of and prevention strategies for hepatocellular carcinoma.Semin Oncol2012;39:374-83

[26] Aliberti C,Lonardi S.Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an italian center.J Vasc Interv Radiol2017;28:1495-502

[27] Farinati F,Giacomin A.Italian Liver Cancer (ITALI.CA) group. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group.Liver Int2015;35:223-31

[28] Cabibbo G, Petta S, Barbara M, et al; Italian Liver Cancer (ITA.LI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol. 2017;67:65-71.

[29] Cabibbo G, Celsa C, Calvaruso V, et al; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71:265-73.

[30] Celsa C,Fulgenzi CAM.Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment.Hepatology2025;81:837-52

[31] Reig M.Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).J Hepatol2021;74:1225-33

[32] Cabibbo G,Battaglia S.Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death.Clin Cancer Res2025;31:543-50

[33] Reiberger T,Cabibbo G.EASL position paper on clinical follow-up after HCV cure.J Hepatol2024;81:326-44

[34] Piano S,Bosch J.Mechanisms and implications of recompensation in cirrhosis.JHEP Rep2024;6:101233 PMCID:PMC11617229

[35] Wu J,Qiu X.A noninvasive approach to evaluate tumor immune microenvironment and predict outcomes in hepatocellular carcinoma.Phenomics2023;3:549-64 PMCID:PMC10781918

[36] Fried LP, Tangen CM, Walston J, et al; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-56.

[37] GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459-544. PMCID:PMC5388903

[38] Lai JC,Terrault NA,Hayssen H.Frailty predicts waitlist mortality in liver transplant candidates.Am J Transplant2014;14:1870-9 PMCID:PMC4107151

[39] Lai JC,Dodge JL.Development of a novel frailty index to predict mortality in patients with end-stage liver disease.Hepatology2017;66:564-74 PMCID:PMC5519430

[40] Tandon P, Reddy KR, O’Leary JG, et al; North American Consortium for the Study of End-Stage Liver Disease. A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. Hepatology. 2017;65:217-24.

[41] Tandon P,Thomas L.A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the clinical frailty scale.Am J Gastroenterol2016;111:1759-67

[42] Carey EJ,Aqel BA.Six-minute walk distance predicts mortality in liver transplant candidates.Liver Transpl2010;16:1373-8

[43] Sinclair M,Dodge JL.Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist.World J Gastroenterol2017;23:899-905 PMCID:PMC5296207

[44] Dunn MA,Tevar AD.Frailty as tested by gait speed is an independent risk factor for cirrhosis complications that require hospitalization.Am J Gastroenterol2016;111:1768-75

[45] Montano-Loza AJ,Prado CM.Muscle wasting is associated with mortality in patients with cirrhosis.Clin Gastroenterol Hepatol2012;10:166-73

[46] Montano-Loza AJ,Meza-Junco J.Inclusion of sarcopenia within MELD (MELD-sarcopenia) and the prediction of mortality in patients with cirrhosis.Clin Transl Gastroenterol2015;6:e102 PMCID:PMC4816259

[47] Tantai X,Yeo YH.Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis.J Hepatol2022;76:588-99

[48] Montano-Loza AJ.Skeletal muscle abnormalities and outcomes after liver transplantation.Liver Transpl2014;20:1293-5

[49] DiMartini A,Dew MA.Muscle mass predicts outcomes following liver transplantation.Liver Transpl2013;19:1172-80 PMCID:PMC4382961

[50] Kremer WM,Reuter M.Validation of the clinical frailty scale for the prediction of mortality in patients with liver cirrhosis.Clin Transl Gastroenterol2020;11:e00211 PMCID:PMC7386350

[51] Bhanji RA,Moynagh MR.Differing impact of sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease.Liver Transpl2019;25:14-24 PMCID:PMC7187989

[52] Lai JC,Verna EC.Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study.Gastroenterology2019;156:1675-82 PMCID:PMC6475483

[53] Essam Behiry M,Yamany A.Ability of the short physical performance battery frailty index to predict mortality and hospital readmission in patients with liver cirrhosis.Int J Hepatol2019;2019:8092865 PMCID:PMC6521460

[54] Tapper EB,Mittleman MA,Lai M.Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis.Hepatology2015;62:584-90 PMCID:PMC4768731

[55] Thuluvath PJ,Savva Y.Karnofsky performance status before and after liver transplantation predicts graft and patient survival.J Hepatol2018;69:818-25

[56] Lai JC,McCulloch CE.The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis.Am J Gastroenterol2018;113:235-42 PMCID:PMC5866923

[57] Lai JC, Shui AM, Duarte-Rojo A, et al; from the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study. Frailty, mortality, and health care utilization after liver transplantation: from the multicenter functional assessment in liver transplantation (FrAILT) study. Hepatology. 2022;75:1471-9. PMCID:PMC9117399

[58] Kardashian A,McCulloch CE.Identifying an optimal liver frailty index cutoff to predict waitlist mortality in liver transplant candidates.Hepatology2021;73:1132-9 PMCID:PMC7710552

[59] Lai JC, Dodge JL, Kappus MR, et al; Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J Hepatol. 2020;73:575-81. PMCID:PMC7438309

[60] Wang M,Ruck J.Clinically relevant cut-points for changes in the liver frailty index are associated with waitlist mortality in patients with cirrhosis.Liver Transpl2024;30:991-1001 PMCID:PMC11792089

[61] Wang M,Ganger D.Liver transplantation provides survival benefit at all levels of frailty: from the multicenter functional assessment in liver transplantation study.Hepatology2025;81:1269-75 PMCID:PMC11757801

[62] Yamada S,Morine Y.Significance of frailty in prognosis after hepatectomy for elderly patients with hepatocellular carcinoma.Ann Surg Oncol2021;28:439-46

[63] Okada T,Shinkawa H.Impact of frailty on long-term outcomes after liver resection for hepatocellular carcinoma in elderly patients: a prospective study.Asian J Surg2024;47:147-53

[64] Yang T,Qiu W.The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: a multicenter cohort study.Am J Surg2024;237:115761

[65] Ramai D,Kewalramani A.Hospital frailty risk score is independently associated with mortality and encephalopathy in hospitalized patients with hepatocellular carcinoma.Biomedicines2021;9:1693 PMCID:PMC8615905

[66] Tandon P,Lai JC,Merli M.Sarcopenia and frailty in decompensated cirrhosis.J Hepatol2021;75 Suppl 1:S147-62 PMCID:PMC9125684

[67] Guo Y,Zhu L,Zheng C.Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis.Sci Rep2023;13:934 PMCID:PMC9845331

[68] Beumer BR, van Vugt JLA, Sapisochin G, et al; Collaborators. Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria. J Cachexia Sarcopenia Muscle. 2022;13:2373-82. PMCID:PMC9530497

[69] Cederholm T.Overlaps between frailty and sarcopenia definitions.Nestle Nutr Inst Workshop Ser2015;83:65-9

[70] Cruz-Jentoft AJ, Bahat G, Bauer J, et al; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16-31. PMCID:PMC6593317

[71] Lai JC,Bernal W.Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases.Hepatology2021;74:1611-44 PMCID:PMC9134787

[72] Nishikawa H,Hiramatsu A,Hino K.Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria.Hepatol Res2016;46:951-63

[73] Ii ER, Satapathy SK. Sarcopenia in the cirrhotic patient: current knowledge and future directions.J Clin Exp Hepatol2023;13:162-77 PMCID:PMC9840086

[74] Jiang C,Fu W.Association between sarcopenia and prognosis of hepatocellular carcinoma: a systematic review and meta-analysis.Front Nutr2022;9:978110 PMCID:PMC9794869

[75] Liu J,Huang L.Prevalence of sarcopenia among patients with hepatocellular carcinoma: a systematic review and metaanalysis.Oncol Lett2023;26:283 PMCID:PMC10236145

[76] Nikolaou D.Sarcopenia and frailty: the detectable overlapping and the possible diagnostic approaches.JFSF2016;01:08-12

[77] Kichena S,Fricke B.Potential of prehabilitation in hepatocellular carcinoma: a narrative review of available evidence.Ann Palliat Med2024;13:101-11

[78] Stout NL,Lyons KD,Silver JK.A systematic review of rehabilitation and exercise recommendations in oncology guidelines.CA Cancer J Clin2021;71:149-75 PMCID:PMC7988887

[79] Christopher CN,Wilson RL.Exercise and nutrition interventions for prehabilitation in hepato-pancreato-biliary cancers: a narrative review.Nutrients2023;15:5044 PMCID:PMC10745391

[80] Marcantei C,King J,Armand A.Effects of exercise training on muscle mass and physical function in patients with hepatocellular carcinoma after diagnosis: a systematic review.Dig Dis Sci2024;69:2667-80

[81] Brustia R,Skurzak S.Guidelines for perioperative care for liver transplantation: enhanced recovery after surgery (ERAS) recommendations.Transplantation2022;106:552-61

[82] Joliat GR,Hasegawa K.Guidelines for perioperative care for liver surgery: enhanced recovery after surgery (ERAS) society recommendations 2022.World J Surg2023;47:11-34 PMCID:PMC9726826

[83] Muscaritoli M,Bachmann P.ESPEN practical guideline: clinical nutrition in cancer.Clin Nutr2021;40:2898-913

[84] Bischoff SC,Dasarathy S.ESPEN practical guideline: clinical nutrition in liver disease.Clin Nutr2020;39:3533-62

[85] Toh EQ,Wang JDJ,Tan YF.Prehabilitation programs in liver resection: a narrative review.Chin Clin Oncol2024;13:9

[86] Jetten WD,Van Meeteren NLU,Klaase JM.Physical effects, safety and feasibility of prehabilitation in patients awaiting orthotopic liver transplantation, a systematic review.Transpl Int2022;35:10330 PMCID:PMC9492850

[87] Benmassaoud A,Carli F.Prehabilitation in patients awaiting liver transplantation.Transplant Rev2024;38:100835

[88] Loschi TM,Della Guardia B,Boteon APCS.Exercise training as an intervention for frailty in cirrhotic patients on the liver transplant waiting list: a systematic review.World J Hepatol2023;15:1153-63 PMCID:PMC10642435

[89] Lin FP,Bloomer PM.Prehabilitation-driven changes in frailty metrics predict mortality in patients with advanced liver disease.Am J Gastroenterol2021;116:2105-17

[90] Hallsworth K, McCain MV, Fallen-Bailey R, Brown MC, Orange ST, Reeves HL. Is home-based, virtually delivered, group exercise feasible and acceptable for older patients with hepatocellular carcinoma? A non-randomised feasibility study (TELEX-Liver Cancer). BMJ Open. 2024;14:e082155. PMCID:PMC11177682

[91] Colosimo S,Saffioti F.Use of branched-chain amino acids as a potential treatment for improving nutrition-related outcomes in advanced chronic liver disease.Nutrients2023;15:4190 PMCID:PMC10574343

[92] Ruiz-Margáin A,Moreno-Guillén P.Nutritional therapy for hepatocellular carcinoma.World J Gastrointest Oncol2021;13:1440-52 PMCID:PMC8529929

[93] Espina S,Bernal-Monterde V,García-Mateo S.Evaluation and management of nutritional consequences of chronic liver diseases.Nutrients2023;15:3487 PMCID:PMC10421025

[94] Berardi G,Sposito C.Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.Hepatology2023;77:1527-39 PMCID:PMC10121838

[95] Plank LD,Peng S.Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial.Hepatology2008;48:557-66

[96] Zhang Y,Zhang L,Li L.Branched-chain amino acids in liver diseases: complexity and controversy.Nutrients2024;16:1875 PMCID:PMC11206364

[97] van Dijk AM,Portincasa P.Systematic review with meta-analysis: branched-chain amino acid supplementation in liver disease.Eur J Clin Invest2023;53:e13909

[98] Sideris GA,Vyllioti AT.The role of branched-chain amino acid supplementation in combination with locoregional treatments for hepatocellular carcinoma: systematic review and meta-analysis.Cancers2023;15:926 PMCID:PMC9913329

[99] Chen L,Wang X.Efficacy and safety of oral branched-chain amino acid supplementation in patients undergoing interventions for hepatocellular carcinoma: a meta-analysis.Nutr J2015;14:67 PMCID:PMC4496824

[100] Yap KY,Ng S,Shelat VG.Effect of perioperative branched chain amino acids supplementation in liver cancer patients undergoing surgical intervention: a systematic review.World J Gastrointest Surg2023;15:2596-618 PMCID:PMC10725538

[101] Wong CS,Liau SS.Perioperative immunonutrition in hepatectomy: a systematic review and meta-analysis.Ann Hepatobiliary Pancreat Surg2020;24:396-414 PMCID:PMC7691191

[102] Gao B,Liu Y.Clinical efficacy of perioperative immunonutrition containing omega-3-fatty acids in patients undergoing hepatectomy: a systematic review and meta-analysis of randomized controlled trials.Ann Nutr Metab2020;76:375-86

[103] Zhang C,Li F.Effect of ω-3 polyunsaturated fatty acids on liver function and inflammatory reaction in patients undergoing hepatectomy: a systematic review and meta-analysis of randomized control trials.Expert Rev Gastroenterol Hepatol2019;13:375-84

[104] Lei Q,Zheng H,Tan S.Peri-operative immunonutrition in patients undergoing liver transplantation: a meta-analysis of randomized controlled trials.Asia Pac J Clin Nutr2015;24:583-90

[105] Plank LD,Gane EJ.Perioperative immunonutrition in patients undergoing liver transplantation: a randomized double-blind trial.Hepatology2015;61:639-47

[106] Ss S, Pottakkat B. Effect of immunonutrition on the liver function status of end-stage liver disease patients waiting/referred for liver transplant: a randomized controlled trial.Cureus2023;15:e36923 PMCID:PMC10148730

[107] Graf J.Psychological burden and psycho-oncological interventions for patients with hepatobiliary cancers-a systematic review.Front Psychol2021;12:662777 PMCID:PMC8131509

[108] Li L,Ge Y.The perioperative experience and needs of hepatocellular carcinoma patients in interventional therapy: a phenomenological qualitative study.Eur J Gastroenterol Hepatol2024;36:423-9

[109] Wang J,Fu A.A randomized clinical trial of comprehensive education and care program compared to basic care for reducing anxiety and depression and improving quality of life and survival in patients with hepatocellular carcinoma who underwent surgery.Medicine2019;98:e17552 PMCID:PMC6946196

[110] Zhang X,Wu D,Fu S.The effect of 5A nursing intervention on living quality and self-care efficacy of patients undergoing chemotherapy after hepatocellular carcinoma surgery.Am J Transl Res2021;13:6638-45 PMCID:PMC8290751

[111] Grimmett C,Chambers S.Psychological interventions prior to cancer surgery: a review of reviews.Curr Anesthesiol Rep2022;12:78-87 PMCID:PMC8801554

[112] Delabays C,Joliat GR.Enhanced recovery after liver surgery in cirrhotic patients: a systematic review and meta-analysis.Perioper Med2024;13:24 PMCID:PMC10983761

[113] Noba L,Chandler C,Hariharan D.Enhanced recovery after surgery (ERAS) reduces hospital costs and improve clinical outcomes in liver surgery: a systematic review and meta-analysis.J Gastrointest Surg2020;24:918-32 PMCID:PMC7165160

[114] Tinguely P,Ramirez-Del Val A.Enhanced recovery after surgery programs improve short-term outcomes after liver transplantation-a systematic review and meta-analysis.Clin Transplant2021;35:e14453

[115] Cillo U,Polacco M.Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit.Hepatology2017;65:1741-8

[116] Cillo U,Volk ML.The survival benefit of liver transplantation in hepatocellular carcinoma patients.Dig Liver Dis2010;42:642-9

[117] European Association for the Study of the Liver. Electronic address: [e-mail]. EASL Clinical Practice Guidelines: Liver transplantation.J Hepatol2016;64:433-85

[118] Aduen JF,Dickson RC.Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years.Mayo Clin Proc2009;84:973-8 PMCID:PMC2770908

[119] Su F,Berry K.Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit.Gastroenterology2016;150:441-53.e6

[120] Gulla A,Juchneviciute I.A narrative review: predicting liver transplant graft survival using artificial intelligence modeling.Front Transplant2024;3:1378378 PMCID:PMC11235265

[121] Romero-Cristóbal M,Fernández-Yunquera A.Demographic trends in liver transplant survivors after 3 decades of program implementation: the impact of cohort and period effects on life expectancy.Transplant Direct2024;10:e1684 PMCID:PMC11288611

[122] Yong CM,Ochoa V.Multivessel coronary artery disease predicts mortality, length of stay, and pressor requirements after liver transplantation.Liver Transpl2010;16:1242-8

[123] Martinez-Perez S,Davierwala PM.Perioperative cardiovascular risk assessment and management in liver transplant recipients: a review of the literature merging guidelines and interventions.J Cardiothorac Vasc Anesth2024;38:1015-30

[124] Pagano G,Blasi A.CACS, CCTA and mCAD-LT score in the pre-transplant assessment of coronary artery disease and the prediction of post-transplant cardiovascular events.Liver Int2024;44:1912-23

[125] Alvarez J,Daily M.Tipping the scales: liver transplant outcomes of the super obese.J Gastrointest Surg2016;20:1628-35

[126] Cullaro G,Lee BP.Chronic kidney disease in liver transplant candidates: a rising burden impacting post-liver transplant outcomes.Liver Transpl2020;26:498-506 PMCID:PMC8056970

[127] Soldera J,Rech MM.Predicting major adverse cardiovascular events after orthotopic liver transplantation using a supervised machine learning model: a cohort study.World J Hepatol2024;16:193-210 PMCID:PMC10941741

[128] Abdelhameed A,Feng J.Deep learning-based prediction modeling of major adverse cardiovascular events after liver transplantation.Mayo Clin Proc Digit Health2024;2:221-30 PMCID:PMC11238640

[129] Mancuso A,Cabibbo G.Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.Dig Liver Dis2015;47:324-30

[130] Bang K,Yoo C.Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.Cancer Med2023;12:2572-9 PMCID:PMC9939097

[131] Cillo U, Carraro A, Avolio AW, et al; Italian Board of Experts in Liver Transplantation (I-BELT). Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT). Updates Surg. 2024;76:725-41.

[132] Kaibori M, Yoshii K, Yokota I, et al; Liver Cancer Study Group of Japan. Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg. 2019;269:692-9.

[133] Tan LLY,Syn N.Effect of age on the short- and long-term outcomes of patients undergoing curative liver resection for HCC.Eur J Surg Oncol2022;48:1339-47

[134] Okinaga H,Hasegawa K,Kokudo N.Short-term outcomes following hepatectomy in elderly patients with hepatocellular carcinoma: an analysis of 10,805 septuagenarians and 2,381 Octo- and Nonagenarians in Japan.Liver Cancer2018;7:55-64 PMCID:PMC5892364

[135] Lee JS,Ryoo S,Choi GH.Efficacy and safety of surgical resection in elderly patients with hepatocellular carcinoma: a systematic review and meta-analysis.Gut Liver2024;18:695-708 PMCID:PMC11249930

[136] Lu Y,Lu WF.The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis.Clin Res Hepatol Gastroenterol2023;47:102147

[137] Cauchy F,Dokmak S.Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome.Br J Surg2013;100:113-21

[138] Viganò L,Cescon M.Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC.J Hepatol2015;63:93-101

[139] Berardi G,Sposito C.Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome.JHEP Rep2024;6:101075 PMCID:PMC11220535

[140] Molinari M,Samra PB.Hepatic resection for hepatocellular carcinoma in nonalcoholic fatty liver disease: a systematic review and meta-analysis of 7226 patients.Ann Surg Open2021;2:e065 PMCID:PMC10455059

[141] Lanari J,Billato I.Textbook outcome and nomogram-guided approaches for enhancing surgical success in elderly HCC patients: deciphering the influence of sarcopenia.Updates Surg2024;76:2645-54 PMCID:PMC11602817

[142] Polvieng T,Thienhiran A,Fuengfoo P.Effect of sarcopenia on the prognosis of clinical outcomes in patients with hepatocellular carcinoma after hepatic resection.Am Surg2024;90:1447-55

[143] Kobayashi A,Hamaguchi Y.Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma.Ann Surg2019;269:924-31

[144] Giakoustidis A,Chatzikomnitsa P.The effects of sarcopenia on overall survival and postoperative complications of patients undergoing hepatic resection for primary or metastatic liver cancer: a systematic review and meta-analysis.J Clin Med2024;13:3869 PMCID:PMC11242440

[145] Gani F,Amini N.Frailty as a risk predictor of morbidity and mortality following liver surgery.J Gastrointest Surg2017;21:822-30

[146] Tanaka S,Iida H.Preoperative assessment of frailty predicts age-related events after hepatic resection: a prospective multicenter study.J Hepatobiliary Pancreat Sci2018;25:377-87

[147] Osei-Bordom D,Hodson J.Impact of frailty on short-term outcomes after laparoscopic and open hepatectomy.World J Surg2022;46:2444-53 PMCID:PMC9436876

[148] Voron T,Pietrasz D.Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma.Ann Surg2015;261:1173-83

[149] Berardi G,Colasanti M.Association of sarcopenia and body composition with short-term outcomes after liver resection for malignant tumors.JAMA Surg2020;155:e203336 PMCID:PMC7512123

[150] Marasco G,Serenari M.Sarcopenia predicts major complications after resection for primary hepatocellular carcinoma in compensated cirrhosis.Cancers2022;14:1935 PMCID:PMC9025609

[151] Snowden CP,Anderson HL.Submaximal cardiopulmonary exercise testing predicts complications and hospital length of stay in patients undergoing major elective surgery.Ann Surg2010;251:535-41

[152] Carli F.Prehabilitation to enhance perioperative care.Anesthesiol Clin2015;33:17-33

[153] Yu Q,Navuluri R.Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.Abdom Radiol2021;46:4467-75

[154] South E,Anwer S.The effectiveness of ablative and non-surgical therapies for early hepatocellular carcinoma: systematic review and network meta-analysis of randomised controlled trials.Cancer Med2023;12:20759-72 PMCID:PMC10709740

[155] Cillo U,Fasolo E.Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: results of 815 procedures.J Surg Oncol2019;120:956-65

[156] Cillo U, Noaro G, Vitale A, et al; HePaTIC Study Group. Laparoscopic microwave ablation in patients with hepatocellular carcinoma: a prospective cohort study. HPB. 2014;16:979-86. PMCID:PMC4487748

[157] Gerges FJ,Jabbour-Khoury SI.Anesthesia for laparoscopy: a review.J Clin Anesth2006;18:67-78

[158] Hoffmann R,Schmidt D,Claussen CD.Prolonged antibiotic prophylaxis in patients with bilioenteric anastomosis undergoing percutaneous radiofrequency ablation.J Vasc Interv Radiol2012;23:545-51

[159] Skonieczki BD,Wasser EJ.Radiofrequency and microwave tumor ablation in patients with implanted cardiac devices: is it safe?.Eur J Radiol2011;79:343-6

[160] Ibrahim SM,Sato KT.Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.World J Gastroenterol2008;14:1664-9 PMCID:PMC2695906

[161] Lyu N,Li JB.Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1).J Clin Oncol2022;40:468-80

[162] He M,Zou R.Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial.JAMA Oncol2019;5:953-60 PMCID:PMC6512278

[163] Fründt TW,von Felden J.Equal efficacy and safety profile in elderly patients with hepatocellular carcinoma receiving palliative treatment.Cancers2022;14:768 PMCID:PMC8833746

[164] Tang Q,Liang J.Efficacy and safety of transarterial chemoembolization in elderly patients of advanced hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.Front Oncol2021;11:646410 PMCID:PMC8293292

[165] Sun Z,Fang Y.Efficacy and safety of raltitrexed-eluting CalliSpheres® bead transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma: a single-arm, prospective study.Ther Adv Med Oncol2024;16:17588359241229661 PMCID:PMC10868504

[166] Schindler P,Rennebaum F.Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis.J Cancer Res Clin Oncol2024;150:235 PMCID:PMC11074216

[167] Zhang L,Wang Z,Liang B.Safety and effectiveness of transarterial chemoembolization in hepatocellular carcinoma patients aged greater versus less than 80 years.Clin Interv Aging2023;18:1883-92 PMCID:PMC10656852

[168] Lin WC,Chang CW,Chen MJ.Challenges of transarterial therapy for hepatocellular carcinoma in patients with chronic kidney disease.Medicine2019;98:e17007 PMCID:PMC6736401

[169] Hsu CY,Su CW.Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency.J Clin Gastroenterol2010;44:e171-7

[170] Yeh H,Yen TH.Hepatocellular carcinoma in patients with renal dysfunction: pathophysiology, prognosis, and treatment challenges.World J Gastroenterol2021;27:4104-42 PMCID:PMC8311541

[171] Giannini EG, Aglitti A, Borzio M, et al; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.CA cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice. Cancers. 2019;11:1689. PMCID:PMC6896125

[172] Gordan JD,Abou-Alfa GK.Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline.J Clin Oncol2020;38:4317-45

[173] Vogel A, Martinelli E; ESMO Guidelines Committee. Electronic address: [e-mail]; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801-5.

[174] Bruix J,Galle PR,Sangro B.Systemic treatment of hepatocellular carcinoma: an EASL position paper.J Hepatol2021;75:960-74

[175] Cabibbo G,Borzio M.Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part II - Non-surgical treatments.Dig Liver Dis2024;56:394-405

[176] Marrero JA,Venook AP.Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study.J Hepatol2016;65:1140-7

[177] Vithayathil M,Fulgenzi CAM.Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.Liver Int2022;42:2538-47 PMCID:PMC9825835

[178] Hajiev S,Motedayеn Aval L.Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.Br J Cancer2021;124:407-13 PMCID:PMC7852559

[179] Di Costanzo GG,De Luca M.Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.Med Oncol2013;30:446

[180] Li D,Merle P.Atezolizumab plus bevacizumab versus sorafenib for unresectable hepatocellular carcinoma: results from older adults enrolled in the imbrave150 randomized clinical trial.Liver Cancer2022;11:558-71 PMCID:PMC9801180

[181] Alkadimi MA,Lucero KT.Clinical characteristics, treatment patterns, and outcomes of patients with locally advanced/metastatic hepatocellular carcinoma treated at the veterans health administration.Oncologist2024;29:369-76 PMCID:PMC11067802

[182] Song BG,Kang W.Analysis of factors predicting the real-world efficacy of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma.Gut Liver2024;18:709-18 PMCID:PMC11249941

[183] Carballo-Folgoso L,Lorca R.Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.Liver Int2021;41:2200-11

[184] Rimassa L,Pressiani T.Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.Cancer Treat Rev2019;77:20-8

[185] Nishida N.Liver damage related to immune checkpoint inhibitors.Hepatol Int2019;13:248-52

[186] Leonardi GC,Altan M.Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders.J Clin Oncol2018;36:1905-12 PMCID:PMC6553840

[187] Johnson DB,Menzies AM.Immune checkpoint inhibitors in challenging populations.Cancer2017;123:1904-11 PMCID:PMC5445005

[188] Waller K,Lai E.The liver frailty index predicts survival in systemic therapy for hepatocellular carcinoma: a multicentre prospective cohort study.ESMO Gastrointest Oncol2024;3:100043